Welcome to the Annual Meeting of Stockholders for Serina Therapeutics. Our host for today's meeting is Simba Gill, Co-Executive Chairman. I will now turn the conference over to your host. Mr. Gill, you may begin. Good afternoon, welcome to the 2026 Annual Meeting of Stockholders of Serina Therapeutics, Inc. I'm Simba Gill, Co-Executive Chairman of Serina's Board of Directors. I hereby call the meeting to order. On behalf of the Board of Directors and management of the company, we'd like to thank you for your attendance and support of Serina. It is now my pleasure to introduce Serina's Chief Executive Officer and Corporate Secretary, Steve Ledger, who will act as Secretary of the meeting. Thanks, Simba. We are joined today by a representative of our independent registered public accounting firm, Frazier & Deeter LLC. Although Frazier & Deeter, LLC has indicated that it does not wish to make a statement, the firm representative will be available to respond to appropriate questions during the general question- and- answer period following the end of the meeting. We are conducting this meeting in accordance with our amended and restated bylaws and the rules of conduct and procedures for this meeting. Stockholders may submit questions at any time during this meeting in the space provided on the virtual meeting screen. During the meeting, we will only respond to questions regarding the items that are on the Agenda for the meeting. Questions of general concern to stockholders will be addressed following the end of the meeting. While we will respond to appropriate questions about matters to be considered at today's meeting and questions of general interest to investors about our business, we will not be providing updates on our ongoing strategic process in this meeting. If there are any matters of individual concern to a stockholder and not of general concern to all stockholders, they should be raised after the conclusion of the meeting. Some questions may not be appropriate to address during today's meeting. If your question is not answered, please contact Investor Relations at investor.relations@serinatherapeutics.com at the conclusion of the meeting. R ules of Conduct and Procedures, Proxy Statement, and Agenda are available on the virtual meeting screen. In the unlikely event of a technical malfunction or disruption that interferes with our ability to continue the meeting, the meeting will be adjourned, recessed, or expedited. If we are not able to announce a time and date for the meeting to resume, then we will make a public announcement via a filing with the SEC. As a reminder, stockholders attending the virtual meeting can vote their shares online until the closing of the polls by logging into the meeting website as a stockholder and clicking the link provided to cast votes. You will need the control number provided with your proxy materials to vote. Voting online will revoke any proxy previously submitted for such shares. If you have previously voted by proxy and do not wish to change your vote, your vote will be cast as you previously instructed and no further action is required. The meeting is being held, one, to elect three directors. Two, to vote on the share increase proposal. Three, to vote on the 2024 Incentive Plan Amendment Proposal. Four, to vote on the Conversion Proposal. Five, to vote on the Private Placement Proposal. Six, to vote on the Say- on- Pay Proposal on an advisory basis. Seven, to vote on the Say- on- Pay Frequency Proposal on an advisory basis. Eight, to ratify the appointment of Frazier & Deeter, LLC for Serina's auditors for 2026. Following this meeting, the Inspector of Elections will finalize its count of the proxies and ballots. We will report the final vote results in a filing with the SEC. A list of the registered holders of our common stock as of the April 20th, 2026 record date has been on file and available at Serina's corporate headquarters for inspection by any stockholder for the past 10 days. This list of stockholders is available for examination during the meeting in accordance with the company's amended and restated bylaws by accessing the link in the virtual portal entitled Stockholders List. I have an affidavit of mailing confirming that the Notice of Annual M eeting, Proxy Statement, and Proxy Card were previously made available in a timely manner to our stockholders. These documents will be included in the minutes of this meeting. Serina Therapeutics has appointed a representative of our outside legal counsel, Bradley Arant, to act as Inspector of the Election. Scott Ludwig from Bradley Arant is with us today. His oath of office has been delivered to us and will be included in the minutes of this meeting. The record date for this meeting was April 20th, 2026. A majority of the shares of our common stock outstanding, as of the record date, are present either in person or represented by proxy. As a result, I hereby declare a quorum is present. We may proceed with the meeting. Thank you, Steve. The polls are now open for voting on all matters to be presented. After voting has been completed on all matters on the Agenda, I will close the polls. As more fully described in the company's Proxy Statement, eight proposals are to be considered and acted upon at the meeting. Proposal 1, Election of Directors. The first proposal to come before the meeting is the election of three directors to serve as members of the Board of Directors until the next annual meeting of stockholders of the company that coincides with the expiration of such members' applicable terms and until their respective successors are elected and have been qualified. The names of the Board of Directors nominees to serve until the 2029 Annual Meeting are Gregory H. Bailey, MD, Richard Marshall, CBE, MD, PhD, Jay Venkatesan, MD. No stockholder nominations were received prior to the deadline established in the company's Amended and Restated Bylaws. No additional nominations may be made at this meeting, I declare the nominations to be closed. The board recommends a vote for each of the board's director nominees. Proposal 2, Approval of Share Increase Proposal. The second proposal to come before the meeting is the approval of the Share Increase Proposal, as more fully described in our Proxy Statement filed with the SEC on April 27th, 2026. Our board has approved seeking stockholder authorization for the Share Increase Proposal and recommends that our stockholders approve the Share Increase Proposal. Proposal 3, approval of 2024 Incentive Plan Amendment Proposal. The third proposal to come before the meeting is the approval of the 2024 Incentive Plan Amendment Proposal, as more fully described in our Proxy Statement. Our board has approved seeking stockholder authorization for the 2024 Incentive Plan Amendment Proposal and recommends that our stockholders approve the 2024 Incentive Plan Amendment Proposal. Proposal 4, approval of Conversion Proposal. The fourth proposal to come before the meeting is the approval of the Conversion Proposal, as more fully described in our Proxy Statement. Our board has approved seeking stockholder authorization for the Conversion Proposal and recommends that our stockholders approve the Conversion Proposal. Proposal 5, approval of Private Placement Proposal. The fifth proposal to come before the meeting is the approval of the Private Placement Proposal, as more fully described in our Proxy Statement. Our board has approved seeking stockholder authorization for the Private Placement Proposal and recommends that our stockholders approve the Private Placement Proposal. Proposal 6, approval of Say- on- Pay Proposal. The sixth proposal to come before the meeting is the approval, on an advisory basis, of the Say- on- Pay Proposal, as more fully described in our Proxy Statement. Our board has approved seeking stockholder authorization for the Say- on- Pay Proposal and recommends that our stockholders approve the Say- on- Pay Proposal. Proposal 7, approval of Say- on -Pay Frequency Proposal. The seventh proposal to come before the meeting is the approval, on an advisory basis, of the Say- on- Pay Frequency Proposal, as more fully described in our Proxy Statement. Our board has approved seeking stockholder authorization for the Say- on- Pay frequency proposal and recommends that our stockholders vote for a frequency of every three years on the Say- on-P ay Frequency Proposal. Proposal 8, Ratification of Appointment of Independent Registered Public Accounting Firm. The eighth and final proposal to come before the meeting is the ratification of the appointment of Frazier & Deeter, LLC as the company's independent registered public accounting firm for the 2026 fiscal year. Although not required by law, the board has determined to request stockholder approval of our selection of an independent registered public accounting firm and recommends a vote for Proposal 8. These eight proposals are the only matters for a vote at this meeting. If you're a stockholder of record or a proxy holder for each stockholder and you wish to vote at this meeting, please do so at this time using the ballot in the section of the virtual meeting portal entitled Stockholder Ballot. The polls will be closing shortly. We will take a brief pause for stockholders to submit any remaining ballots. At this time, I will also see if there are any questions from stockholders with respect to the eight proposals. There are no questions at this time. Thank you. It appears that everybody has had the opportunity to vote, and there are no further questions from stockholders. I now declare the polls closed with respect to all items of business. I'd now ask Steve to present the results of the vote. Thank you, Simba. I've been informed by the Inspector of Elections that the preliminary vote report shows that the nominees for election to the board have been duly elected. The Share Increase Proposal, the 2024 Incentive Plan Amendment Proposal, the Conversion Proposal, and the Private Placement Proposal have been approved. The Say-on-Pay Proposal and the ratification of Frazier & Deeter, LLC as the company's independent registered public accounting firm for 2026 have been approved by advisory vote, and a frequency of every one year for the Say-on-Pay Frequency Proposal has been approved by advisory vote. We will report the final vote results to the SEC in a Form 8-K within four business days. Thank you, Steve. That concludes the business for today's meeting. We are hereby adjourned. Ladies and gentlemen, thank you for attending today's meeting. We will now proceed to the stockholder question- and- answer session. At this time, I will now pause to see if there are any questions of general interest from stockholders. We have no questions from our stockholders. That concludes the question- and- answer session. This concludes today's meeting. Thank you for attending. You may now disconnect and have a wonderful rest of your day